Stephens analyst Scott Fidel lowered the firm’s price target on Centene to $87 from $95 and keeps an Overweight rating on the shares. Centene provided "rather detailed granularity into its modeling assumptions" and also reset its 2024 EPS floor to greater than $6.60 from its prior view of great than $7.15, notes the analyst, who thinks the company’s latest assumptions "represent a relatively conservative view on Medicaid redeterminations" compared to peers for 2023-2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CNC:
- Centene price target lowered to $87 from $94 at Credit Suisse
- Centene price target lowered to $86 from $90 at Barclays
- Early notable gainers among liquid option names on April 25th
- Centene raises FY23 adjusted EPS view to at least $6.40 from $6.25-$6.40
- Centene reports Q1 adjusted EPS $2.11, consensus $2.10